Premium
Genetic profile of naïve untreated primary cutaneous melanomas with a negative sentinel lymph node
Author(s) -
Yang K.,
Oh K. S.,
Mahalingam M.
Publication year - 2020
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.14321
Subject(s) - cdkn2a , neuroblastoma ras viral oncogene homolog , medicine , biopsy , sentinel lymph node , pathology , oncology , dermatology , cancer research , cancer , kras , breast cancer , colorectal cancer
Sentinel lymph node (SLN) biopsy is typically offered to patients with primary cutaneous melanomas (PCMs) of ≥ 1 mm depth, but not all SLNs are positive using this cutoff. To ascertain whether positivity is genetically regulated, genetic analysis was performed using an augmented enrichment‐based next‐generation DNA and RNA sequencing assay in SLN‐negative (Group 1, n = 8, mean depth 1.3 mm) and SLN‐positive PCMs (controls, Group 2, n = 4, mean depth 1.4 mm). In Group 1, the mean number of mutations was 21 (range 3–48) with the most frequent mutations occurring in NF1 (75%) followed by TP53 (63%), CDKN2A and BRAF (38%), and NRAS (25%), while in Group 2, the ean number of mutations was 9.5 (range 5–18) with mutations in NRAS and BRAF being the most frequent (50%) followed by those in ATM, CDKN2A, CDKN2B, and NOTCH1 (25%). Increased frequency of NF1‐inactivating mutations in Group 1 provides provocative early data that the presence of NF1 mutations might confer a less aggressive phenotype.